Harry Kirsch served as Chief Financial Officer of Novartis. During his tenure, he led major strategic transactions, including the spin-off of Alcon, the sale of Novartis’ stake in Roche, and the spin-off of Sandoz.
Prior to this role, he held several regional and global senior finance positions within Novartis, following earlier finance roles at Procter & Gamble in Europe and the United States.